Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
about
Treatment of inflammatory myopathy: emerging therapies and therapeutic targetsScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesRelationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsValidation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of diseaseEvaluation of muscles affected by myositis using magnetic resonance elastography.Idiopathic inflammatory myopathies.Cutaneous dermatomyositis in the era of biologicals.Pathogenesis of dermatomyositis: role of cytokines and interferon.Twins discordant for myositis and systemic lupus erythematosus show markedly enriched autoantibodies in the affected twin supporting environmental influences in pathogenesis.Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damageTocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases.Plasma proteomic profiles from disease-discordant monozygotic twins suggest that molecular pathways are shared in multiple systemic autoimmune diseases.Type I interferon pathway in adult and juvenile dermatomyositis.Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activityResistin in idiopathic inflammatory myopathies.Beyond the MHC: A canine model of dermatomyositis shows a complex pattern of genetic risk involving novel loci.Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.Phenotypes of Peripheral Blood Lymphocytes and Cytokine Expression in Polymyositis and Dermatomyositis before Treatment and after Clinical Remission.Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease courseAberrant expression of cytokine interleukin 9 along with interleukin 4 and interferon γ in connective tissue disease-associated interstitial lung disease: association with severity of pulmonary fibrosis.Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis.The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomesModern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Correlation between the frequency of Th17 cell and the expression of microRNA-206 in patients with dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patientsConsensus-based recommendations for the management of juvenile dermatomyositis.Suppression of soluble T cell-associated proteins by an anti-interferon-α monoclonal antibody in adult patients with dermatomyositis or polymyositis.Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositisCan muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies?Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.Immunotherapeutic implication of IL-6 blockade.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Gene expression and regulation in systemic lupus erythematosus.Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.Immunological biomarkers in dermatomyositis.
P2860
Q26796546-6E450126-DC06-4ED8-BBEF-74FCA08A4A64Q26798209-36A7FBE9-25C8-4261-BE9F-84EEA1D5AAE8Q28290930-A16473CC-E733-4974-8AEC-43CA26A96B8CQ28652726-79BB7851-DFA8-406F-841A-BF3762C6D1F4Q30469107-86707445-CC0A-42B6-B73D-207F03A985B0Q33924451-CED2D7D7-D24D-4F6E-A690-E9223F7B818BQ34501531-CFD0B8DD-0AF1-4622-8667-0F9B8FBEFCE2Q34626955-F6600DC1-3411-4590-A78D-50BD6FF95A4BQ35112489-1BF261E5-5FC4-429D-9054-385E4708ECA2Q35125063-69D6EA0C-A74E-482C-9EC9-8A1481601465Q35724900-99BC24B7-6868-4EBA-9E1E-18A7A17F8B00Q35838076-110A75C2-96E2-4A60-8B2B-C2B039B204DBQ35861492-7A89A382-C05B-4E18-A4B8-51A85AE0563BQ35907790-F9AB7634-4163-4189-A021-8772ED54F30CQ36108080-0F226AC9-5074-4326-B84B-7C2780997C57Q36245680-8DC20D3B-1F51-438C-A336-531B1E229C56Q36245955-4D558D28-7A99-4687-A9F5-715D2F928230Q36269554-EDDF0AF2-8ACF-4D6A-B52D-D11318E23801Q36312962-EB0F6A51-EC98-4F51-8666-0ACC2A9CCD9DQ36346324-2B67D27D-A51B-4D7E-88C2-226E0D223050Q36434501-6F237256-6A75-4CD0-93DC-19B4D559D6A7Q36582317-1E9E6FA8-F54A-412A-BA07-47A15929F37AQ36942366-C9A9C6FD-0961-4B3B-B0CF-64A530A2EA04Q37022721-23C15CB5-FF31-45E2-8B3E-A48E5EB52B9FQ37095730-3D5E10A8-EA8D-4E51-820A-B3ECFE4B8FD4Q37316232-B2962791-A855-4DB6-8A83-BCBE9E8299BEQ37368405-5916BB03-68A2-4EB6-A8C9-08ED50D948B8Q37465544-F0460AF5-16DA-4487-87C1-5DAA68A64C6DQ37617000-861F0AD2-903B-406D-8DBC-340A6E6C5593Q37674711-EB4A0FFB-E28D-4E92-84C4-106275A2CB26Q37689900-E3EDD8FF-FFDA-4A08-B22E-1FBFE7995ADDQ37825936-FA87268E-F754-4973-99D8-C72FFBEA5DB1Q37906737-3E8A13E0-56B3-4E8A-B3CA-1EFC3683FB72Q37938701-F4037BCD-24F0-460F-B0DF-05F2ED9C9715Q37965754-CD9F8BBC-8A82-4B2D-B97A-2B968C3551CAQ38023207-A270D91F-9AC3-4EAC-B74A-D1E802D8C640Q38125510-CFE5014A-2A52-4794-AE7B-3B5CC5E1CF2CQ38221095-B7430F4E-C435-43A7-9E29-BBC296D77E55Q38244567-C337FEC5-C06A-466E-80F4-1B8AEF1BF0D6Q38592676-93DBD57D-B3FD-4224-BA45-92010FB4A6B1
P2860
Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@en
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@nl
type
label
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@en
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@nl
prefLabel
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@en
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@nl
P2093
P2860
P356
P1476
Interleukin-6 and type I inter ...... e activity in dermatomyositis.
@en
P2093
Ann M Reed
Brant Newman
Emily C Baechler
Erik J Peterson
Hatice Bilgic
Jason W Bauer
Joseph C Wilson
Kelly T McNallan
Shreyasee Amin
Sonja Ellingson
P2860
P304
P356
10.1002/ART.24936
P577
2009-11-01T00:00:00Z